electroacupuncture
electroacupuncture
Overview
Electroacupuncture is a form of acupuncture in which small electrical currents are applied through needles inserted at selected points. It is used as a therapeutic intervention in both clinical and experimental settings, particularly in pain management, neurological disorders, and rehabilitation research. In biomedical studies, electroacupuncture is often investigated not only as a symptomatic treatment but also as a modulator of inflammatory signaling, autophagy, apoptosis, angiogenesis, and synaptic plasticity.
Recent research has examined electroacupuncture in relation to pathways such as SIRT1, NF-κB, VEGF/Akt1/ERK, ELAVL1/SIRT1/FOXO1, and TLR4/P2X7-NLRP3, reflecting interest in its potential to influence neuroprotection, immune regulation, and tissue repair. Across animal models and early clinical studies, electroacupuncture has been explored as a complementary therapy for ischemic stroke, intracerebral hemorrhage, chronic low back pain, paclitaxel-induced peripheral neuropathic pain, depressive-like behavior, sarcopenia, and other conditions.
Focus of Latest Publications
Recent publications have used electroacupuncture as an experimental intervention across a range of disease models, with a strong emphasis on pain modulation and neuroprotection.
In a mouse model of Complete Freund's adjuvant (CFA)-induced inflammatory pain, EA was tested for its effects on mechanical allodynia and anxiety-like behaviors. The study combined behavioral testing with chemogenetic manipulation of glutamatergic projections from the spinal dorsal horn to the lateral parabrachial nucleus, indicating that EA may reduce pain-related affective symptoms by suppressing excitatory signaling in the spinoparabrachial pathway.
In a study of paclitaxel-induced peripheral neuropathic pain, EA was evaluated for analgesic effects and possible involvement of the TLR4/P2X7-NLRP3 signaling pathway. This work supports the idea that EA may attenuate neuropathic pain through modulation of innate immune and inflammasome-related signaling.
EA has also been studied in acute gouty arthritis using MSU-induced GA rats, where it was reported to alleviate arthritis by inhibiting NLRP3 inflammasome activation through modulation of the circadian-inflammation axis. This links EA not only to inflammatory suppression but also to regulation of the circadian clock, suggesting a broader role in time-dependent immune control.
In models of ischemic stroke, EA was repeatedly associated with neuroprotection and recovery. One study reported that EA promotes angiogenesis and ameliorates dysregulated autophagy after ischemic stroke via the ELAVL1/SIRT1/FOXO1 pathway. Another found that EA promotes synaptic recovery after cerebral ischemia-reperfusion by activating SIRT1, inhibiting the NF-κB pathway, and regulating astrocyte phenotypic transformation. A separate study combined EA with neural stem cell transplantation and reported enhanced neurogenesis and functional recovery, with associated changes in tsRNA expression. Together, these studies position EA as a potential adjunctive strategy for post-stroke repair, affecting vascular, synaptic, glial, and gene-regulatory processes.
In a study of intracerebral hemorrhage, EA at GV20-GB7 was reported to regulate mitophagy and protect against neurological deficits via inhibition of apoptosis. Although this publication was later marked with an expression of concern, it reflects ongoing interest in EA as a modulator of mitochondrial quality control and cell survival pathways in acute brain injury.
EA has also been examined in depressive-like behavior in chronic unpredictable mild stress rats, where it was reported to enhance autophagy and reduce hippocampal neuroinflammation through the VEGF/Akt1/ERK pathway. This suggests a possible role for EA in neuropsychiatric conditions through immune-metabolic and plasticity-related mechanisms.
In chronic nonspecific low back pain, a pilot study assessed the acute effects of a single EA session on purinergic signaling and inflammatory markers in 23 patients. This clinical work indicates that EA may influence extracellular nucleotide signaling and inflammatory responses in humans, although the study was exploratory.
EA has also been investigated in older adults with sarcopenia, where it was combined with the Otago exercise Program in a randomized controlled study. This reflects interest in EA as an adjunct to exercise-based rehabilitation for age-related muscle decline.
Across these studies, EA is consistently presented as a multimodal intervention with potential effects on pain, inflammation, apoptosis, autophagy, angiogenesis, synaptic repair, and behavioral outcomes. The recurring involvement of pathways such as SIRT1/HIF-1α, nuclear factor kappa B, CASP1, SQSTM1, and anti-inflammatory cytokines underscores its broad mechanistic relevance in preclinical biomedical research.